The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Prostate Cancer MORE >>

Survival was increased with the treatment of enzalutamide plus standard of care compared with the use of other non-steroidal anti-androgens plus SOC for patients with metastatic hormone-sensitive prostate cancer. Results from an interim analysis of the phase III ENZAMET trial presented at the 2019 ASCO Annual Meeting showed that 80% of men with mHSPC were alive after 3 years with enzalutamide treatment compared with 72%. 

Latest JournalAll Journals >>

Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.